Neurodegenerative Disorder News and Research

RSS

Parkinson’s disease imposes €22.8 billion economic burden across Europe

The annual societal cost of Parkinson's disease across Europe reached €22.8 billion in 2019, equivalent to €28.8 billion at 2025 prices, a new study published today in Movement Disorders has shown.

27 Aug 2026

New retina model reveals how CLN3-Batten disease damages vision

Researchers have developed a new way to study CLN3-Batten disease, a rare, inherited condition that causes early vision loss in children followed by progressive neurological decline.

26 Aug 2026

Tea, berries and dark chocolate featured in a diet linked to lower Parkinson’s risk

A prospective UK Biobank study of 123,655 adults found that a dietary pattern richer in flavonoid-containing foods was modestly associated with a lower incidence of hospital-recorded Parkinson’s disease. The association was strongest among those with the highest flavonoid diet scores, while exploratory proteomic and transcriptomic analyses pointed to possible neuroimmune and cell-adhesion pathways but did not establish causality or mechanism.

26 Aug 2026

New imaging model can detect early brain changes in Huntington's disease

Researchers have shown that an imaging model can detect microstructural abnormalities in the brain associated with Huntington's disease, potentially offering a new method for monitoring disease progression and evaluating new treatments.

11 Aug 2026

3D DNA organization in rare immune cells can explain Crohn's disease risk

A new study co-led by Prof. Valeriya Malysheva, group leader at the VIB-UAntwerp Center for Molecular Neurology, has been published in Nature Genetics.

4 Aug 2026

New genomic approach links rare immune cells to autoimmune disease risk

Much of how genetic risk leads to disease has remained hidden. In many cases, genetic variants linked to disease do not act on nearby genes along the chromosome.

4 Aug 2026

Landmark study identifies new genetic risk factors linked to fibromyalgia syndrome

In a landmark study published in Nature Medicine, an international team of researchers has identified new genetic risk factors associated with fibromyalgia syndrome.

28 Jul 2026

Bee venom boosts the effects of standard Parkinson's therapy

Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons, leading to motor symptoms such as tremors, rigidity, slowed movement, and impaired balance, as well as cognitive decline.

22 Jul 2026

Study reveals why rare neurological disease damages specific brain regions

Many neurological diseases damage specific parts of the brain, even though the harmful protein involved is present throughout the brain.

20 Jul 2026

First clinical trial evaluates stem cell therapy for Huntington's disease

An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease was presented today at the ISSCR 2026 Annual Meeting.

9 Jul 2026

Study finds early-onset Parkinson’s burden has more than doubled worldwide

A GBD 2021 analysis of 204 countries and territories found that early-onset Parkinson’s disease burden among people aged 20 to 49 more than doubled from 1990 to 2021. Age-standardized incidence, prevalence, and disability rates rose globally, with higher estimated burden among males, rapid growth in middle and high-middle SDI regions, and moderate ecological correlations with pesticide use.

1 Jul 2026

Eating eggs regularly reduces Alzheimer’s disease risk

Findings suggest that egg consumption is associated with lower Alzheimer's disease risk, supporting the need for further research on diet and brain health.

8 May 2026

New insights into ALS progression through glial cell behavior

All the core facilities of the Cibio Department of the University of Trento are involved in a study on ALS, co-funded by Fondazione AriSla, national organizations and various donors, to better understand the molecular mechanisms of slow-progressing cases.

5 May 2026

Identifying the ages when Alzheimer’s biomarkers sharply change

New research identifies critical ages for Alzheimer's biomarkers, enhancing screening strategies and understanding neurodegeneration across the aging spectrum.

1 May 2026

Gut microbiome clues may help spot Parkinson’s disease in its earliest phase

Researchers found that a Parkinson’s disease-related gut microbiome pattern appears not only in people with diagnosed Parkinson’s, but also in some non-manifesting GBA1 variant carriers and a subset of healthy individuals. The findings suggest that gut microbiome changes may help flag people who are closer to Parkinson’s disease development, although longitudinal studies are still needed to confirm predictive value.

21 Apr 2026

Alzheimer’s monoclonal antibodies fail to deliver meaningful results

Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps in current therapeutic approaches.

21 Apr 2026

Fat-producing enzyme identified as key driver of damage in Parkinson’s disease

A fat-producing enzyme in brain cells may play a key role in driving damage in Parkinson's disease and could offer a new target for treatment, scientists at Nanyang Technological University, Singapore (NTU Singapore) have found.

9 Apr 2026

Study reveals how tau tangles spread from one brain region to another in Alzheimer's

Alzheimer's disease is a progressive neurodegenerative disorder that slowly impairs memory, affects thinking skills, and eventually interferes with daily functioning.

8 Apr 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

22 Mar 2026

Machine learning detects early brain changes linked to Alzheimer's disease

Worcester Polytechnic Institute (WPI) researchers have used a form of artificial intelligence (AI) to analyze anatomical changes in the brain and predict Alzheimer's disease with nearly 93% accuracy.

5 Mar 2026